Authors
Latest:
Interferon-Based Therapies for Hepatitis C: Utilization, Costs, and OutcomesThis study illustrates the healthcare utilization patterns, direct costs, and sustained virologic response rates associated with interferon-based therapies for hepatitis C patients.
Latest:
AbbVie's New Hepatitis C Treatment Won't Cure Patient Access IssueIssues surrounding patents for curative drugs allow pharmaceutical companies to establish a market monopoly and charge astronomical prices.
Latest:
Many Options Now Available to Treat HyperlipidemiaAdherence to both pharmacologic and nonpharmacologic regimens will result in the largest impact on hyperlipidemia, and patients should be individually assessed to determine the most appropriate ones for them.
Latest:
More Than Ever, Quality Is the Name of the GameNearly 10 years ago, the Institute of Medicine made a statement that could have been read as a call to action for pharmacists.
Latest:
Celebrating 50 Years of ASHP MidyearThe American Society of Health-System Pharmacists has just finished celebrating 50 years of its Midyear Clinical Meeting.
Latest:
Serotonin and Beyond: Optimizing Management of Major Depressive DisorderPharmacists can learn about treatment of major depressive disorder.
Latest:
Medication Use in Bariatric Surgery: Evaluation of Perioperative AdjustmentsA retrospective evaluation to assess whether medications for patients undergoing bariatric procedures are effectively optimized to ensure safe medication transitioning.
Latest:
A Look at TCA Toxicity Presentation and TreatmentIn 2015, American poison centers responded to more than 10,000 tricyclic antidepressant exposures. With this level of prevalence, pharmacists should be prepared to respond to questions regarding TCA toxicity.
Latest:
Pharmacist Provider Status in Spotlight at APhA Annual MeetingA number of speakers at the American Pharmacists Association 2014 Annual Meeting in Orlando emphasized the importance of winning provider status for pharmacists.
Latest:
Examining Recent Advances in Understanding and Treatment of Dry Eye Disease: An Eye on the Pharmacist's RoleThis Continuing Education activity is supported by an educational grant from Alcon, Inc.
Latest:
Carving Out a Niche in the Treatment of Tardive DyskinesiaThe FDA recently approved Ingrezza (valbenazine) for the treatment of adults with tardive dyskinesia.
Latest:
Pharmacists and Annual Wellness VisitsPharmacists are continuing to expand their role as health care providers with more direct patient care opportunities. Pharmacists working under the supervision of a physician can provide an annual wellness visit, which is an exam that focuses on the patient’s health, allowing them the opportunity to develop a personalized approach to health care and disease prevention.
Latest:
Pharmacotherapy Timing in Heart Failure and Impact on Healthcare CostsThe findings of a retrospective study suggest that timing of heart failure (HF)-related pharmacotherapy following a HF-related encounter has potential implications on subsequent healthcare costs.
Latest:
Influenza vs the Common Cold: Symptoms and TreatmentPatients may find it difficult to distinguish between a cold and the flu, and pharmacists can help them determine if self treatment is appropriate.
Latest:
Pharmacist Provider Status Is Growing. Now What?Throughout a new graduate’s career, that provider status will become mainstream.
Latest:
Healthcare Utilization and Costs for Insured Patients With FibromyalgiaFibromyalgia was related to a pattern of initial increase in utilization and costs, followed by a decrease 7 to 12 months after diagnosis.
Latest:
Adult Immunizations: Are Your Patients Up-to-Date?In the health-system setting, pharmacists must often prioritize their attention to treating the most acute medical condition a patient presents with; however, it is important to also consider opportunities to prevent disease.
Latest:
Initiating Drug Therapy in Multiple Sclerosis Patients: Effect on Healthcare CostsMultiple sclerosis (MS) is a disease of inflammatory demyelination of axons of the central nervous system that results in episodes of transient neurologic deficits, progressing to permanent neurologic deterioration over time.1 The cause of MS remains unclear, but it is thought to involve both genetic susceptibility and environmental triggers, possibly viral, which result in self-sustaining autoimmune dysfunction.
Latest:
How Zero-Error E-Prescribing Can Help Pharmacists as They Begin COVID-19 VaccinationsAs administration of COVID-19 begins, pharmacies are preparing to vaccinate millions of people, not only once but twice.
Latest:
Securing Specialty Oncology Contracts in a Data-Driven WorldData aggregation partners can provide value in their ability to pull clinical information from both the HSSP and electronic health records.
Latest:
Total Store Expo, Take 2NACDS anticipates another successful conference in Boston this August.
Latest:
Combo Inhibitor Antibiotic Approved to Treat HABP/VABPThe US Food and Drug Administration has approved Allergan's supplemental New Drug Application to expand the approved use of their cephalosporin / beta-lactamase inhibitor combo antibiotic, AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years of age or older.
Latest:
New Insulin Products and Best PracticesEven with many new developments over the past century, the coordinated use of blood glucose monitors, diabetes medications, and insulin to manage the disease may be too intricate for some patients.
